{"result": {"id": "60c19ac3-3f9f-4d2f-a63e-66d80ae1c72e", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ASIAN PACIFIC HEART ASSOCIATION<|>ORGANIZATION<|>The Asian Pacific Heart Association issued a scientific statement on hypertension management in Eastern Asians.\")\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>The European Society of Cardiology collaborates with the European Society of Hypertension to provide guidelines for hypertension treatment.\")\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>The European Society of Hypertension collaborates with the European Society of Cardiology to provide guidelines for hypertension treatment.\")\n##\n(\"entity\"<|>CAMELOT STUDY<|>EVENT<|>A randomized controlled trial investigating the effect of antihypertensive agents on cardiovascular events in patients with coronary disease.\")\n##\n(\"entity\"<|>TIME STUDY<|>EVENT<|>A prospective, randomized, open-label, blinded-endpoint clinical trial comparing evening versus morning dosing of antihypertensives in the UK.\")\n##\n(\"entity\"<|>ACTION DATABASE<|>EVENT<|>A database used for analysis of benefits of nifedipine GITS in systolic hypertension and combination with RAS blockade.\")\n##\n(\"relationship\"<|>ASIAN PACIFIC HEART ASSOCIATION<|>WANG JIANGUANG<|>Wang Jianguang contributed to a scientific statement issued by the Asian Pacific Heart Association.<|>7)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>EUROPEAN SOCIETY OF HYPERTENSION<|>Both organizations collaborate to provide hypertension treatment guidelines.<|>9)\n##\n(\"relationship\"<|>CAMELOT STUDY<|>NISSEN SE<|>Nissen SE was a researcher involved in the CAMELOT study.<|>8)\n##\n(\"relationship\"<|>TIME STUDY<|>MACKENZIE IS<|>Mackenzie IS was a researcher involved in the TIME study.<|>8)\n##\n(\"relationship\"<|>ACTION DATABASE<|>ELLIOTT HL<|>Elliott HL conducted analysis using the ACTION database.<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559019, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 478, "prompt_tokens": 6287, "total_tokens": 6765, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 6208}, "prompt_cache_hit_tokens": 6208, "prompt_cache_miss_tokens": 79}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �[J]. 中华心血管病杂 志 ,2005,33(7) :613-617.\n[231]  WorldHealthOrganization(WHO) .  Guidelineforthe pharma- cological treatment of hypertension in adults[ M].  Geneva:  WHO,2021:13.\n[232]  ThomopoulosC, BazoukisG, GrassiG, etal. Monotherapy vs combination treatmentsofdifferentcomplexity: a meta-analysis ofblood pressurelowering randomized outcome trials[J]. J Hy-\n\n\npertens,2021,39(5) :846-855.\n[233]  XuW , Goldberg SI, ShubinaM, etal.  Optimal systolic blood pressuretarget, timetointensification, and timetofollow-upin treatmentofhypertension: populationbasedretrospectivecohort study[J]. BMJ,2015,350:h158.\n[234]  王文 ,马丽媛 ,刘明波 ,等.  初始低剂量氨氯地平加替米沙坦或复 方阿米洛利联合治疗对高血压患者血压控制率影响的阶段报告 [J]. 中华心血管病杂志 ,2009,37(8) :701-707.\n[235]  Egan BM, KjeldsenSE, NarkiewiczK, etal. Single-pillcombi- nations, hypertension control and clinical outcomes: potential,  pitfallsand solutions[J]. BloodPress,2022,31(1) :164-168.\n[236]  ReaF, SavaréL, FranchiM, etal. Adherenceto treatmentby initialantihypertensivemono and combination therapies[J]. Am  J Hypertens,2021,34(10) :1083-1091.\n[237]  MackenzieIS, RogersA, PoulterNR, etal. Cardiovascularout- comes in adultswithhypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study) : a prospective,  randomised,  open-label,  blinded-endpoint clinical trial[J]. Lancet,2022,400(10361) :1417-1425.\n[238]  Cooper-DeHoffRM, GongY, HandbergEM, etal. Tightblood pressure control and cardiovascular outcomes among hyperten- sive patients with diabetes and coronary artery disease[J].   JAMA,2010,304(1) :61-68.\n[239]  王文 ,王继光 ,张宇清.  针对中国高血压的特点 ,制定中国高血压 防治的策略与方案[J]. 中华高血压杂志 ,2010,18(10) :904-907.\n[240]  Mancia G, Kjeldsen SE, Kreutz R,  et al.  Individualized beta- blockertreatmentforhighbloodpressuredictatedbymedicalco- morbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension guidelines[J].   Hypertension,2022,79:1153-1166.\n[241]  WangJG, KarioK, LauT, etal. Useofdihydropyridinecalci- um channelblockersinthemanagementofhypertensioninEast- ern Asians: a scientific statementfrom the Asian Pacific Heart Association[J]. HypertensRes,2011,34(4) :423-430.\n[242]  delaSierraA, MateuA, GorostidiM, etal. Antihypertensive therapy and short-term blood pressure variability[J]. J Hyper- tens,2021,39(2) :349-355.\n[243]  WebbAJ, FischerU, MehtaZ, etal. Effectsofantihypertens- ive-drug class on interindividualvariation in blood pressure and risk ofstroke: a systematic review and meta-analysis[J]. Lan- cet,2010,375(9718) :906-915.\n[244]  Law MR, MorrisJK, WaldNJ.  Useofbloodpressurelowering drugsin the prevention ofcardiovascular disease: meta-analysis of147randomised trialsin thecontextofexpectationsfrom pro- spectiveepidemiologicalstudies[J]. BMJ,2009,338:b1665.\n[245]  NissenSE, TuzcuEM, LibbyP, etal. Effectofantihypertens- iveagentsoncardiovasculareventsinpatientswithcoronarydis- easeand normalblood pressure: the CAMELOT study: a ran- domized controlledtrial[J]. JAMA,2004,292(18) :2217-2225.\n[246]  ElliottHL, MeredithPA.  PreferentialbenefitsofnifedipineGITS in systolichypertension and in combination withRASblockade:  furtheranalysisofthe‘ACTION’databaseinpatientswith an- gina[J]. J Hum Hypertens,2011,25(1) :63-70.\n[247]  FurbergCD, PsatyBM, MeyerJV.  Nifedipine.  Dose-relatedin- crease\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>WORLD HEALTH ORGANIZATION (WHO)<|>ORGANIZATION<|>The World Health Organization provides guidelines for the pharmacological treatment of hypertension in adults, based in Geneva.\")\n##\n(\"entity\"<|>GENEVA<|>GEO<|>Geneva is the location where the World Health Organization is based.\")\n##\n(\"entity\"<|>THOMOPOULOS C<|>PERSON<|>Thomopoulos C is a researcher involved in a meta-analysis of blood pressure lowering randomized outcome trials.\")\n##\n(\"entity\"<|>BAZOUKIS G<|>PERSON<|>Bazoukis G is a researcher involved in a meta-analysis of blood pressure lowering randomized outcome trials.\")\n##\n(\"entity\"<|>GRASSI G<|>PERSON<|>Grassi G is a researcher involved in a meta-analysis of blood pressure lowering randomized outcome trials.\")\n##\n(\"entity\"<|>XU W<|>PERSON<|>Xu W is a researcher involved in a population-based retrospective cohort study on hypertension treatment.\")\n##\n(\"entity\"<|>GOLDBERG SI<|>PERSON<|>Goldberg SI is a researcher involved in a population-based retrospective cohort study on hypertension treatment.\")\n##\n(\"entity\"<|>SHUBINA M<|>PERSON<|>Shubina M is a researcher involved in a population-based retrospective cohort study on hypertension treatment.\")\n##\n(\"entity\"<|>WANG WEN<|>PERSON<|>Wang Wen is a researcher involved in studies on hypertension treatment and control rates in China.\")\n##\n(\"entity\"<|>MA LIYUAN<|>PERSON<|>Ma Liyuan is a researcher involved in studies on hypertension treatment and control rates in China.\")\n##\n(\"entity\"<|>LIU MINGBO<|>PERSON<|>Liu Mingbo is a researcher involved in studies on hypertension treatment and control rates in China.\")\n##\n(\"entity\"<|>EGAN BM<|>PERSON<|>Egan BM is a researcher involved in studies on single-pill combinations and hypertension control.\")\n##\n(\"entity\"<|>KJELDSEN SE<|>PERSON<|>Kjeldsen SE is a researcher involved in studies on single-pill combinations and hypertension control.\")\n##\n(\"entity\"<|>NARKIEWICZ K<|>PERSON<|>Narkiewicz K is a researcher involved in studies on single-pill combinations and hypertension control.\")\n##\n(\"entity\"<|>REA F<|>PERSON<|>Rea F is a researcher involved in studies on adherence to antihypertensive mono and combination therapies.\")\n##\n(\"entity\"<|>SAVARE L<|>PERSON<|>Savare L is a researcher involved in studies on adherence to antihypertensive mono and combination therapies.\")\n##\n(\"entity\"<|>FRANCHI M<|>PERSON<|>Franchi M is a researcher involved in studies on adherence to antihypertensive mono and combination therapies.\")\n##\n(\"entity\"<|>MACKENZIE IS<|>PERSON<|>Mackenzie IS is a researcher involved in the TIME study on hypertension treatment timing.\")\n##\n(\"entity\"<|>ROGERS A<|>PERSON<|>Rogers A is a researcher involved in the TIME study on hypertension treatment timing.\")\n##\n(\"entity\"<|>POULTER NR<|>PERSON<|>Poulter NR is a researcher involved in the TIME study on hypertension treatment timing.\")\n##\n(\"entity\"<|>COOPER-DEHOFF RM<|>PERSON<|>Cooper-DeHoff RM is a researcher involved in studies on tight blood pressure control and cardiovascular outcomes.\")\n##\n(\"entity\"<|>GONG Y<|>PERSON<|>Gong Y is a researcher involved in studies on tight blood pressure control and cardiovascular outcomes.\")\n##\n(\"entity\"<|>HANDBERG EM<|>PERSON<|>Handberg EM is a researcher involved in studies on tight blood pressure control and cardiovascular outcomes.\")\n##\n(\"entity\"<|>WANG JIANGUANG<|>PERSON<|>Wang Jianguang is a researcher involved in studies on hypertension management in Eastern Asians.\")\n##\n(\"entity\"<|>KARIO K<|>PERSON<|>Kario K is a researcher involved in studies on hypertension management in Eastern Asians.\")\n##\n(\"entity\"<|>LAU T<|>PERSON<|>Lau T is a researcher involved in studies on hypertension management in Eastern Asians.\")\n##\n(\"entity\"<|>DELA SIERRA A<|>PERSON<|>Dela Sierra A is a researcher involved in studies on antihypertensive therapy and short-term blood pressure variability.\")\n##\n(\"entity\"<|>MATEU A<|>PERSON<|>Mateu A is a researcher involved in studies on antihypertensive therapy and short-term blood pressure variability.\")\n##\n(\"entity\"<|>GOROSTIDI M<|>PERSON<|>Gorostidi M is a researcher involved in studies on antihypertensive therapy and short-term blood pressure variability.\")\n##\n(\"entity\"<|>WEBB AJ<|>PERSON<|>Webb AJ is a researcher involved in a systematic review and meta-analysis on antihypertensive-drug class effects.\")\n##\n(\"entity\"<|>FISCHER U<|>PERSON<|>Fischer U is a researcher involved in a systematic review and meta-analysis on antihypertensive-drug class effects.\")\n##\n(\"entity\"<|>MEHTA Z<|>PERSON<|>Mehta Z is a researcher involved in a systematic review and meta-analysis on antihypertensive-drug class effects.\")\n##\n(\"entity\"<|>LAW MR<|>PERSON<|>Law MR is a researcher involved in a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.\")\n##\n(\"entity\"<|>MORRIS JK<|>PERSON<|>Morris JK is a researcher involved in a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.\")\n##\n(\"entity\"<|>WALD NJ<|>PERSON<|>Wald NJ is a researcher involved in a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.\")\n##\n(\"entity\"<|>NISSEN SE<|>PERSON<|>Nissen SE is a researcher involved in the CAMELOT study on antihypertensive agents and cardiovascular events.\")\n##\n(\"entity\"<|>TUZCU EM<|>PERSON<|>Tuzcu EM is a researcher involved in the CAMELOT study on antihypertensive agents and cardiovascular events.\")\n##\n(\"entity\"<|>LIBBY P<|>PERSON<|>Libby P is a researcher involved in the CAMELOT study on antihypertensive agents and cardiovascular events.\")\n##\n(\"entity\"<|>ELLIOTT HL<|>PERSON<|>Elliott HL is a researcher involved in studies on the benefits of nifedipine GITS in systolic hypertension.\")\n##\n(\"entity\"<|>MEREDITH PA<|>PERSON<|>Meredith PA is a researcher involved in studies on the benefits of nifedipine GITS in systolic hypertension.\")\n##\n(\"entity\"<|>FURBERG CD<|>PERSON<|>Furberg CD is a researcher involved in studies on nifedipine and its effects.\")\n##\n(\"entity\"<|>PSATY BM<|>PERSON<|>Psaty BM is a researcher involved in studies on nifedipine and its effects.\")\n##\n(\"entity\"<|>MEYER JV<|>PERSON<|>Meyer JV is a researcher involved in studies on nifedipine and its effects.\")\n##\n(\"relationship\"<|>WORLD HEALTH ORGANIZATION (WHO)<|>GENEVA<|>The World Health Organization is based in Geneva.<|>9)\n##\n(\"relationship\"<|>THOMOPOULOS C<|>BAZOUKIS G<|>Both researchers collaborated on a meta-analysis of blood pressure lowering randomized outcome trials.<|>7)\n##\n(\"relationship\"<|>THOMOPOULOS C<|>GRASSI G<|>Both researchers collaborated on a meta-analysis of blood pressure lowering randomized outcome trials.<|>7)\n##\n(\"relationship\"<|>BAZOUKIS G<|>GRASSI G<|>Both researchers collaborated on a meta-analysis of blood pressure lowering randomized outcome trials.<|>7)\n##\n(\"relationship\"<|>XU W<|>GOLDBERG SI<|>Both researchers collaborated on a population-based retrospective cohort study on hypertension treatment.<|>7)\n##\n(\"relationship\"<|>XU W<|>SHUBINA M<|>Both researchers collaborated on a population-based retrospective cohort study on hypertension treatment.<|>7)\n##\n(\"relationship\"<|>GOLDBERG SI<|>SHUBINA M<|>Both researchers collaborated on a population-based retrospective cohort study on hypertension treatment.<|>7)\n##\n(\"relationship\"<|>WANG WEN<|>MA LIYUAN<|>Both researchers collaborated on studies on hypertension treatment and control rates in China.<|>7)\n##\n(\"relationship\"<|>WANG WEN<|>LIU MINGBO<|>Both researchers collaborated on studies on hypertension treatment and control rates in China.<|>7)\n##\n(\"relationship\"<|>MA LIYUAN<|>LIU MINGBO<|>Both researchers collaborated on studies on hypertension treatment and control rates in China.<|>7)\n##\n(\"relationship\"<|>EGAN BM<|>KJELDSEN SE<|>Both researchers collaborated on studies on single-pill combinations and hypertension control.<|>7)\n##\n(\"relationship\"<|>EGAN BM<|>NARKIEWICZ K<|>Both researchers collaborated on studies on single-pill combinations and hypertension control.<|>7)\n##\n(\"relationship\"<|>KJELDSEN SE<|>NARKIEWICZ K<|>Both researchers collaborated on studies on single-pill combinations and hypertension control.<|>7)\n##\n(\"relationship\"<|>REA F<|>SAVARE L<|>Both researchers collaborated on studies on adherence to antihypertensive mono and combination therapies.<|>7)\n##\n(\"relationship\"<|>REA F<|>FRANCHI M<|>Both researchers collaborated on studies on adherence to antihypertensive mono and combination therapies.<|>7)\n##\n(\"relationship\"<|>SAVARE L<|>FRANCHI M<|>Both researchers collaborated on studies on adherence to antihypertensive mono and combination therapies.<|>7)\n##\n(\"relationship\"<|>MACKENZIE IS<|>ROGERS A<|>Both researchers collaborated on the TIME study on hypertension treatment timing.<|>7)\n##\n(\"relationship\"<|>MACKENZIE IS<|>POULTER NR<|>Both researchers collaborated on the TIME study on hypertension treatment timing.<|>7)\n##\n(\"relationship\"<|>ROGERS A<|>POULTER NR<|>Both researchers collaborated on the TIME study on hypertension treatment timing.<|>7)\n##\n(\"relationship\"<|>COOPER-DEHOFF RM<|>GONG Y<|>Both researchers collaborated on studies on tight blood pressure control and cardiovascular outcomes.<|>7)\n##\n(\"relationship\"<|>COOPER-DEHOFF RM<|>HANDBERG EM<|>Both researchers collaborated on studies on tight blood pressure control and cardiovascular outcomes.<|>7)\n##\n(\"relationship\"<|>GONG Y<|>HANDBERG EM<|>Both researchers collaborated on studies on tight blood pressure control and cardiovascular outcomes.<|>7)\n##\n(\"relationship\"<|>WANG JIANGUANG<|>KARIO K<|>Both researchers collaborated on studies on hypertension management in Eastern Asians.<|>7)\n##\n(\"relationship\"<|>WANG JIANGUANG<|>LAU T<|>Both researchers collaborated on studies on hypertension management in Eastern Asians.<|>7)\n##\n(\"relationship\"<|>KARIO K<|>LAU T<|>Both researchers collaborated on studies on hypertension management in Eastern Asians.<|>7)\n##\n(\"relationship\"<|>DELA SIERRA A<|>MATEU A<|>Both researchers collaborated on studies on antihypertensive therapy and short-term blood pressure variability.<|>7)\n##\n(\"relationship\"<|>DELA SIERRA A<|>GOROSTIDI M<|>Both researchers collaborated on studies on antihypertensive therapy and short-term blood pressure variability.<|>7)\n##\n(\"relationship\"<|>MATEU A<|>GOROSTIDI M<|>Both researchers collaborated on studies on antihypertensive therapy and short-term blood pressure variability.<|>7)\n##\n(\"relationship\"<|>WEBB AJ<|>FISCHER U<|>Both researchers collaborated on a systematic review and meta-analysis on antihypertensive-drug class effects.<|>7)\n##\n(\"relationship\"<|>WEBB AJ<|>MEHTA Z<|>Both researchers collaborated on a systematic review and meta-analysis on antihypertensive-drug class effects.<|>7)\n##\n(\"relationship\"<|>FISCHER U<|>MEHTA Z<|>Both researchers collaborated on a systematic review and meta-analysis on antihypertensive-drug class effects.<|>7)\n##\n(\"relationship\"<|>LAW MR<|>MORRIS JK<|>Both researchers collaborated on a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.<|>7)\n##\n(\"relationship\"<|>LAW MR<|>WALD NJ<|>Both researchers collaborated on a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.<|>7)\n##\n(\"relationship\"<|>MORRIS JK<|>WALD NJ<|>Both researchers collaborated on a meta-analysis of blood pressure lowering drugs in the prevention of cardiovascular disease.<|>7)\n##\n(\"relationship\"<|>NISSEN SE<|>TUZCU EM<|>Both researchers collaborated on the CAMELOT study on antihypertensive agents and cardiovascular events.<|>7)\n##\n(\"relationship\"<|>NISSEN SE<|>LIBBY P<|>Both researchers collaborated on the CAMELOT study on antihypertensive agents and cardiovascular events.<|>7)\n##\n(\"relationship\"<|>TUZCU EM<|>LIBBY P<|>Both researchers collaborated on the CAMELOT study on antihypertensive agents and cardiovascular events.<|>7)\n##\n(\"relationship\"<|>ELLIOTT HL<|>MEREDITH PA<|>Both researchers collaborated on studies on the benefits of nifedipine GITS in systolic hypertension.<|>7)\n##\n(\"relationship\"<|>FURBERG CD<|>PSATY BM<|>Both researchers collaborated on studies on nifedipine and its effects.<|>7)\n##\n(\"relationship\"<|>FURBERG CD<|>MEYER JV<|>Both researchers collaborated on studies on nifedipine and its effects.<|>7)\n##\n(\"relationship\"<|>PSATY BM<|>MEYER JV<|>Both researchers collaborated on studies on nifedipine and its effects.<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_aaf6ade07576de6a18683214c9d6e4a3662c6ad3c25fb2c1711ac5bdb7d6333f_v2"}